FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Claus-Henning Köhne

Research Profile

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Co-author Network

Publications

TOP 3
Julia Schick; Johanna Tischer; Valentin Vogt; Marion Zerwes; Raymund Buhmann; Andreas Hausmann; Claus-Henning Köhne; Doris Kraemer; T Kroell; Helga Schmetzer
Antileukemic T-cell responses can be predicted by the composition of specific regulatory T-cell subpopulations.
Claus-Henning Köhne; Francesco Pignatti; Ivan Popov; Peter Reichardt; Phillipe Rougier; Manuel Valladares; Jacques Wils; Olivier Bouché; Alfredo Carrato; Losa Gaspà; Christiane Gog; Laurent Bedenne; Frank Biertz
A randomised phase III intergroup trial comparing high-dose infusional 5-fluorouracil with or without folinic acid with standard bolus 5-fluorouracil/folinic acid in the adjuvant treatment of stage III colon cancer: The Pan-European Trial in Adjuvant Colon Cancer 2 study.
Peter Paschka; Mark Ringhoffer; Mathias Rummel; Helmut R Salih; Brigitte Schlegelberger; Richard F Schlenk; Daniela Späth; Marie von Lilienfeld-Toal; Mohammed Wattad; Hartmut Döhner; Juan Du; Verena I Gaidzik; Arnold Ganser; K Götze; Gerhard Held; Heinz-August Horst; Sabine Kayser; Heinz Kirchen; Claus-Henning Köhne; Jürgen Krauter; Andrea Kündgen; Michael Lübbert; Lars Bullinger; Andrea Corbacioglu; Konstanze Döhner
Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG).

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Claus-Henning Köhne (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Julia Schick; Johanna Tischer; Valentin Vogt; Marion Zerwes; Raymund Buhmann; Andreas Hausmann; Claus-Henning Köhne; Doris Kraemer; T Kroell; Helga Schmetzer
Antileukemic T-cell responses can be predicted by the composition of specific regulatory T-cell subpopulations.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2013;36(4):223-37.
2013: Claus-Henning Köhne; Francesco Pignatti; Ivan Popov; Peter Reichardt; Phillipe Rougier; Manuel Valladares; Jacques Wils; Olivier Bouché; Alfredo Carrato; Losa Gaspà; Christiane Gog; Laurent Bedenne; Frank Biertz
A randomised phase III intergroup trial comparing high-dose infusional 5-fluorouracil with or without folinic acid with standard bolus 5-fluorouracil/folinic acid in the adjuvant treatment of stage III colon cancer: The Pan-European Trial in Adjuvant Colon Cancer 2 study.
European journal of cancer (Oxford, England : 1990) 2013;49(8):1868-75.
2013: Peter Paschka; Mark Ringhoffer; Mathias Rummel; Helmut R Salih; Brigitte Schlegelberger; Richard F Schlenk; Daniela Späth; Marie von Lilienfeld-Toal; Mohammed Wattad; Hartmut Döhner; Juan Du; Verena I Gaidzik; Arnold Ganser; K Götze; Gerhard Held; Heinz-August Horst; Sabine Kayser; Heinz Kirchen; Claus-Henning Köhne; Jürgen Krauter; Andrea Kündgen; Michael Lübbert; Lars Bullinger; Andrea Corbacioglu; Konstanze Döhner
Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG).
Blood 2013;121(1):170-7.
2013: István Láng; Philippe Rougier; Ute Sartorius; Desmond Curran; Gunnar Folprecht; Ingolf Griebsch; Erika Hitre; Claus-Henning Köhne; Eric Van Cutsem
Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin.
European journal of cancer (Oxford, England : 1990) 2013;49(2):439-48.
2012: Sandra Gottschling; David F Heigener; Esther Herpel; Peter Klein; Claus-Henning Köhne; Cornelius Kortsik; Thomas Kuhnt; Michael Meister; Ines Moldenhauer; Thomas Muley; Helge G Bischoff; Wilfried E E Eberhardt; Jürgen R Fischer; Philipp A Schnabel; Michael Thomas; Roland Penzel
The gefitinib long-term responder (LTR)--a cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP).
Lung cancer (Amsterdam, Netherlands) 2012;77(1):183-91.
2012: Carsten Bokemeyer; Ilhan Celik; Fortunato Ciardiello; Eric Van Cutsem; Steffen Heeger; Philippe Rougier; Michael Schlichting; Claus-Henning Köhne
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials.
European journal of cancer (Oxford, England : 1990) 2012;48(10):1466-75.
2012: Verena I Gaidzik; Ulrich Germing; K Götze; Detlef Haase; Marianne Habdank; Gerhard Held; Heinz-August Horst; Claus-Henning Köhne; Peter Paschka; Richard F Schlenk; Daniela Späth; Marie von Lilienfeld-Toal; Martin Bentz; Lars Bullinger; Hartmut Döhner; Konstanze Döhner
TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(12):1350-7.
2012: Marc Peeters; Claus-Henning Köhne; Allen Cohn; Jean-Yves Douillard
Panitumumab in combination with cytotoxic chemotherapy for the treatment of metastatic colorectal carcinoma.
Clinical colorectal cancer 2012;11(1):14-23.
2012: Sabine Kayser; Claus-Henning Köhne; Jürgen Krauter; Carina Morlok; David Nachbaur; Mathias Rummel; Brigitte Schlegelberger; Richard F Schlenk; Daniela Späth; Veronica Teleanu; Marie von Lilienfeld-Toal; Sibylla Wilhelm; Manuela Zucknick; Hartmut Döhner; Konstanze Döhner; Arnold Ganser; Ulrich Germing; Gudrun Göhring; K Götze; Gerhard Held; Heinz A Horst
Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies.
Blood 2012;119(2):551-8.
2012: Josef Thaler; Henry Letocha; Laurent Mineur; Ana Baños; Eva Fernebro; Erick Gamelin; Richard Greil; Ralf Hofheinz; Meinolf Karthaus; Claus-Henning Köhne
Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study.
BMC cancer 2012;12():438.
2011: Eric Van Cutsem; Claus-Henning Köhne; István Láng; Gunnar Folprecht; Marek P Nowacki; Stefano Cascinu; Igor Shchepotin; Joan Maurel; D Cunningham; Sabine Tejpar; Michael Schlichting; Angela Zubel; Ilhan Celik; Philippe Rougier; Fortunato Ciardiello
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(15):2011-9.
2011: Eric Van Cutsem; Emilio Bajetta; Juan Valle; Claus-Henning Köhne; Malcolm Moore; Colin Germond; William Berg; Bee-Lian Chen; Tarja Jalava; David Lebwohl; Gerold Meinhardt; Dirk Laurent; J Randolph Hecht; Edward Lin
Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(15):2004-10.
2011: Christian Asseburg; Martin Frank; Claus-Henning Köhne; Jörg Thomas Hartmann; Ingolf Griebsch; Andrea Mohr; Ulrike Osowski; Jeltje Schulten; Thomas Mittendorf
Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
Clinical therapeutics 2011;33(4):482-97.
2011: Sabine Kayser; Konstanze Döhner; Jürgen Krauter; Claus-Henning Köhne; Heinz A Horst; Gerhard Held; Marie von Lilienfeld-Toal; Sibylla Wilhelm; Andrea Kündgen; K Götze; Mathias Rummel; David Nachbaur; Brigitte Schlegelberger; Gudrun Göhring; Daniela Späth; Carina Morlok; Manuela Zucknick; Arnold Ganser; Hartmut Döhner; Richard F Schlenk
The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML.
Blood 2011;117(7):2137-45.
2011: Bernd Metzner; Jochen Casper; Gernot Hartung; Bernd Rosien; Erhard Hölzle; Peter Pelzer; Claus-Henning Köhne
Long-term remissions in metastatic malignant melanoma following chemotherapy and tamoxifen maintenance.
Onkologie 2011;34(4):208-9.
2010: Sanne Lugthart; Stefan Gröschel; Berna Beverloo; Sabine Kayser; Peter J M Valk; Shama Lydia van Zelderen-Bhola; Gert Jan Ossenkoppele; Edo Vellenga; Eva van den Berg-de Ruiter; Urs Schanz; Gregor Verhoef; Peter Vandenberghe; Augustin Ferrant; Claus-Henning Köhne; Michael Pfreundschuh; Heinz A Horst; Elisabeth Koller; Marie von Lilienfeld-Toal; Martin Bentz; Arnold Ganser; Brigitte Schlegelberger; Martine Jotterand; Jürgen Krauter; Thomas Pabst; Matthias Theobald; Richard F Schlenk; Ruud Delwel; Konstanze Döhner; Bob Löwenberg; Hartmut Döhner
Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3890-8.
2010: Gunnar Folprecht; Thomas Gruenberger; Wolf O Bechstein; Hans-Rudolf Raab; Florian Lordick; Jörg T Hartmann; Hauke Lang; Andrea Frilling; Jan Stoehlmacher; Jürgen Weitz; Ralf Konopke; Christian Stroszczynski; Torsten Liersch; Detlev Ockert; Thomas Herrmann; Eray Goekkurt; Fabio Parisi; Claus-Henning Köhne
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
The lancet oncology 2010;11(1):38-47.
2009: John L Marshall; Aimery de Gramont; Claus-Henning Köhne; J L Marshall; Aimery de Gramont; C-H Köhne
Accomplishments in 2008 in the adjuvant treatment of colon cancer.
Gastrointestinal cancer research : GCR 2009;3(5 Supplement 2):S2-7.
2009: Claus-Henning Köhne; Udo Vanhoefer; Gernot Hartung
Clinical predictive factors.
European journal of cancer (Oxford, England : 1990) 2009;45 Suppl 1():43-9.
2009: Claus-Henning Köhne; Heinz-Josef Lenz
Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer.
The oncologist 2009;14(5):478-88.
2009: Daniel J Sargent; Claus-Henning Köhne; Hanna Sanoff; Brian M Bot; Matthew T Seymour; Aimery de Gramont; Ranier Porschen; Leonard B Saltz; Philippe Rougier; Christophe Tournigand; Jean-Yves Douillard; Richard J Stephens; Axel Grothey; Richard M Goldberg
Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(12):1948-55.
2009: Eric Van Cutsem; Claus-Henning Köhne; Erika Hitre; Jerzy Zaluski; Chung-Rong Chang Chien; Anatoly Makhson; Geert D'Haens; Tamás Pintér; Robert Lim; György Bodoky; Jae Kyung Roh; Gunnar Folprecht; Paul Ruff; Christopher Stroh; Sabine Tejpar; Michael Schlichting; Johannes Nippgen; Philippe Rougier
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
The New England journal of medicine 2009;360(14):1408-17.
2008: Jürg Bernhard; Daniel Dietrich; Werner Scheithauer; Daniela Gerber; György Bodoky; Thomas Ruhstaller; Bengt Glimelius; Emilio Bajetta; Johannes Schüller; Piercarlo Saletti; Jean Bauer; Arie Figer; Bernhard C Pestalozzi; Claus-Henning Köhne; Walter Mingrone; Salomon M Stemmer; Karin Tàmas; Gabriela V Kornek; Dieter Koeberle; Richard Herrmann
Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(22):3695-701.
2008: Claus-Henning Köhne; J De Greve; J T Hartmann; I Lang; P Vergauwe; K Becker; Dietrich Braumann; E Joosens; L Müller; J Janssens; C Bokemeyer; P Reimer; H Link; Ernst Späth-Schwalbe; H-J Wilke; H Bleiberg; J Van Den Brande; M Debois; U Bethe; E Van Cutsem
Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(5):920-6.
2008: Claus-Henning Köhne; Gunnar Folprecht; Richard M Goldberg; Emmanuel Mitry; Philippe Rougier
Chemotherapy in elderly patients with colorectal cancer.
The oncologist 2008;13(4):390-402.
2008: Gunnar Folprecht; Matthew T Seymour; Leonard B Saltz; Jean-Yves Douillard; Hartmut Hecker; Richard J Stephens; Timothy S Maughan; Eric Van Cutsem; Philippe Rougier; Emmanuel Mitry; Ute Schubert; Claus-Henning Köhne
Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(9):1443-51.
2008: Gunnar Folprecht; Josep Tabernero; Claus-Henning Köhne; Charles Zacharchuk; Luis Paz-Ares; Federico Rojo; Susan Quinn; Esther Casado; Ramon Salazar; Richat Abbas; Chantal Lejeune; Irene Marimón; Jordi Andreu; Ulrike Ubbelohde; Hernan Cortes-Funes; Jose Baselga
Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(1):215-23.
2008: Eric Van Cutsem; Cornelius Van de Velde; A Roth; Florian Lordick; Claus-Henning Köhne; Stefano Cascinu; Matti Aapro
Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group.
European journal of cancer (Oxford, England : 1990) 2008;44(2):182-94.
2007: Bernard Nordlinger; Eric Van Cutsem; Philippe Rougier; Claus-Henning Köhne; Marc Ychou; Alberto Sobrero; Rene Adam; Dag Arvidsson; Alfredo Carrato; Vassilis Georgoulias; FELICE GIULIANTE; Bengt Glimelius; Markus Golling; Thomas Gruenberger; Josep Tabernero; Harpreet Wasan; Graeme Poston
Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group.
European journal of cancer (Oxford, England : 1990) 2007;43(14):2037-45.
2007: Cornelis J A Punt; Marc Buyse; Claus-Henning Köhne; Peter Hohenberger; Roberto Labianca; Hans J Schmoll; Lars Påhlman; Alberto Sobrero; Jean-Yves Douillard
Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials.
Journal of the National Cancer Institute 2007;99(13):998-1003.
2007: Richard Herrmann; György Bodoky; Thomas Ruhstaller; Bengt Glimelius; Emilio Bajetta; Johannes Schüller; Piercarlo Saletti; Jean Bauer; Arie Figer; Bernhard C Pestalozzi; Claus-Henning Köhne; Walter Mingrone; Salomon M Stemmer; Karin Tàmas; Gabriela V Kornek; Dieter Koeberle; Susanne Cina; Jürg Bernhard; Daniel Dietrich; Werner Scheithauer
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(16):2212-7.
2007: Stefan Boeck; K Weigang-Köhler; M Fuchs; Erika Kettner; Detlef Quietzsch; J Trojan; O Stötzer; S Zeuzem; Florian Lordick; Claus-Henning Köhne; H Kröning; T Steinmetz; H Depenbrock; Volker Heinemann
Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(4):745-51.
2007: Gunnar Folprecht; Claus-Henning Köhne; Manfred P Lutz
Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.
Cancer treatment and research 2007;134():425-40.
2007: Heiko Fensterer; Bernhard Radlwimmer; Jörn Sträter; Malte Buchholz; Daniela E Aust; Catherine Julié; François Radvanyi; Bernard Nordlinger; Claudio Belluco; Eric Van Cutsem; Claus-Henning Köhne; Hans A Kestler; Carsten Schwaenen; Michelle Nessling; Manfred P Lutz; Peter Lichter; Thomas M Gress
Matrix-comparative genomic hybridization from multicenter formalin-fixed paraffin-embedded colorectal cancer tissue blocks.
BMC cancer 2007;7():58.
2006: Eric Van Cutsem; Bernard Nordlinger; Rene Adam; Claus-Henning Köhne; Carmelo Pozzo; Graeme Poston; Marc Ychou; Philippe Rougier
Towards a pan-European consensus on the treatment of patients with colorectal liver metastases.
European journal of cancer (Oxford, England : 1990) 2006;42(14):2212-21.
2006: Claus-Henning Köhne
Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? Against the proposal.
The lancet oncology 2006;7(6):516-7.
2006: Gunnar Folprecht; Manfred P Lutz; P Schöffski; Thomas Seufferlein; A Nolting; P Pollert; Claus-Henning Köhne
Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(3):450-6.
2006: Jana Babatz; Christoph Röllig; Bärbel Löbel; Gunnar Folprecht; Michael Haack; Heinrich Günther; Claus-Henning Köhne; Gerhard Ehninger; Marc Schmitz; Martin Bornhäuser
Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells.
Cancer immunology, immunotherapy : CII 2006;55(3):268-76.
2006: Claus-Henning Köhne; Gunnar Folprecht
On prejudice and facts and choices.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(2):185-7.
2006: Fabio Efficace; andrew bottomley; Corneel Coens; Kristel van Steen; Thierry Conroy; Patrick Schöffski; Hans Schmoll; Eric Van Cutsem; Claus-Henning Köhne
Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer?
European journal of cancer (Oxford, England : 1990) 2006;42(1):42-9.
2005: Gunnar Folprecht; Claus-Henning Köhne
Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting.
Nature clinical practice. Oncology 2005;2(11):578-87.
2005: Claus-Henning Köhne; Eric Van Cutsem; Jacques A Wils; Carsten Bokemeyer; Mustafa El-Serafi; Manfred P Lutz; M Lorenz; Peter Reichardt; H Rückle-Lanz; N Frickhofen; R Fuchs; H-G Mergenthaler; T Langenbuch; Udo Vanhoefer; Philippe Rougier; R Voigtmann; L Müller; Bruno Genicot; O Anak; Bernard Nordlinger
Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(22):4856-65.
2005: Gunnar Folprecht; A Grothey; S Alberts; H-R Raab; Claus-Henning Köhne
Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(8):1311-9.
2005: Matti S Aapro; Claus-Henning Köhne; Harvey Jay Cohen; Martine Extermann
Never too old? Age should not be a barrier to enrollment in cancer clinical trials.
The oncologist 2005;10(3):198-204.
2004: Gunnar Folprecht; D Cunningham; P Ross; B Glimelius; F Di Costanzo; J Wils; W Scheithauer; P Rougier; E Aranda; H Hecker; Claus-Henning Köhne
Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(9):1330-8.
2004: Claus-Henning Köhne; Caroline Bruce; Gunnar Folprecht; Riccardo Audisio
Role of new agents in the treatment of colorectal cancer.
Surgical oncology 2004;13(2-3):75-81.
2004: Gunnar Folprecht; Claus-Henning Köhne
[New therapy options in colorectal carcinoma].
Therapeutische Umschau. Revue thérapeutique 2004;61(6):373-8.
2004: Eberhard Schleyer; Stefan Pursche; Claus-Henning Köhne; Ulrich Schuler; Ulf Renner; Harald Gschaidmeier; Jens Freiberg-Richter; Traugott Leopold; Andreas Jenke; M Bonin; T Bergemann; Philipp le Coutre; M Gruner; Martin Bornhäuser; Oliver G Ottmann; Gerhard Ehninger
Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;799(1):23-36.
2004: Claus-Henning Köhne; Gunnar Folprecht
Current perspectives in the treatment of metastatic colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15 Suppl 4():iv43-53.
2004: Gunnar Folprecht; Claus-Henning Köhne
The role of new agents in the treatment of colorectal cancer.
Oncology 2004;66(1):1-17.
2004: Gunnar Folprecht; Claus-Henning Köhne
[Principles of postoperative therapy in rectal carcinoma].
Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen 2004;75(1):32-7.
2003: Claus-Henning Köhne
[Palliative therapy of colorectal cancer].
Onkologie 2003;26 Suppl 7():41-7.
2003: Jörg Thomas Hartmann; Karin Oechsle; Detlef Quietzsch; Axel Wein; Ralf-Dieter Hofheinz; Friedemann Honecker; O Nehls; Claus-Henning Köhne; G Käfer; Lothar Kanz; Carsten Bokemeyer
Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study.
British journal of cancer 2003;89(11):2051-6.
2003: Claus-Henning Köhne; Jacques A Wils; M Lorenz; Patrick Schöffski; R Voigtmann; Carsten Bokemeyer; M Lutz; C Kleeberg; K Ridwelski; R Souchon; Mustafa El-Serafi; U Weiss; O Burkhard; H Rückle; M Lichnitser; T Langenbuch; W Scheithauer; Benoît Baron; ML Couvreur; Hans-Joachim Schmoll
Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(20):3721-8.
2003: Claus-Henning Köhne; Raphael Catane; B Klein; M Ducreux; Peter C Thuss-Patience; N Niederle; M Gips; Peter Preusser; A Knuth; M Clemens; R Bugat; I Figer; Adi Shani; B Fages; D Di Betta; C Jacques; H J Wilke
Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial.
British journal of cancer 2003;89(6):997-1001.
2003: Alexander Kiani; Claus-Henning Köhne; Thorsten Franz; Jens Passauer; Thorsten Haufe; Peter Gross; Gerhard Ehninger; Eberhard Schleyer
Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment.
Cancer chemotherapy and pharmacology 2003;51(3):266-70.
2003: Michel Ducreux; Claus-Henning Köhne; Gary K Schwartz; Udo Vanhoefer
Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14 Suppl 2():ii17-23.
2003: Friedemann Honecker; Claus-Henning Köhne; Carsten Bokemeyer
Colorectal cancer in the elderly: is palliative chemotherapy of value?
Drugs & aging 2003;20(1):1-11.
2002: Michael Steiner; Peter Schuff-Werner; Mathias Freund; Claus-Henning Köhne
Combined chemotherapy trials require combined pharmacogenetic approaches.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(5):1425-6.
2002: Claus-Henning Köhne; D Cunningham; B Glimelius; Geert H Blijham; E Aranda; W Scheithauer; P Rougier; M Palmer; Jacques A Wils; Benoît Baron; F Pignatti; Patrick Schöffski; S Micheel; F Di Costanzo; H Hecker
Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(2):308-17.
2002: Silke Radetzki; Claus-Henning Köhne; Clarissa von Haefen; Bernhard Gillissen; Isrid Sturm; Bernd Dörken; Peter Daniel
The apoptosis promoting Bcl-2 homologues Bak and Nbk/Bik overcome drug resistance in Mdr-1-negative and Mdr-1-overexpressing breast cancer cell lines.
Oncogene 2002;21(2):227-38.
2002: Claus-Henning Köhne
[Capsule instead of infusion--new oral chemotherapy option].
Krankenpflege Journal 2002;40(1-2):42-3.
2001: Matthias Lorenz; H H Mueller; E Mattes; Heinz-Jochen Gassel; T Junginger; H D Saeger; Harald Schramm; Elsbeth Staib-Sebler; Gregor Vetter; Stefan Heinrich; Claus-Henning Köhne
Phase II study of weekly 24-hour intra-arterial high-dose infusion of 5-fluorouracil and folinic acid for liver metastases from colorectal carcinomas.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(3):321-5.
2001: Henrik Petrowsky; Isrid Sturm; O Graubitz; David A Kooby; Elsbeth Staib-Sebler; Christiane Gog; Claus-Henning Köhne; Timo Hillebrand; Peter Daniel; Yuman Fong; Matthias Lorenz
Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2001;27(1):80-7.
2000: Albrecht Kretzschmar; Peter Reichardt; Peter C Thuss-Patience; P Hohenberger; Thomas Benter; Bernd Dörken; Claus-Henning Köhne
Weekly 24-hour infusion of high-dose 5-fluorouracil plus folinic acid in combination with mitomycin C for the treatment of advanced gastric cancer.
Oncology 2000;59(1):14-7.
2000: Matthias Lorenz; Stefan Heinrich; Elsbeth Staib-Sebler; Claus-Henning Köhne; J Wils; B Nordlinger; Albrecht Encke
Regional chemotherapy in the treatment of advanced pancreatic cancer--is it relevant?
European journal of cancer (Oxford, England : 1990) 2000;36(8):957-65.
1999: Matthias Lorenz; Hans-Helge Müller; Elsbeth Staib-Sebler; Gregor Vetter; Christiane Gog; Henrik Petrowsky; Claus-Henning Köhne
Relevance of neoadjuvant and adjuvant treatment for patients with resectable liver metastases of colorectal carcinoma.
Langenbeck's archives of surgery / Deutsche Gesellschaft für Chirurgie 1999;384(4):328-38.
1999: Isrid Sturm; Claus-Henning Köhne; Gerhard Wolff; Henrik Petrowsky; Timo Hillebrand; Steffen Hauptmann; Matthias Lorenz; Bernd Dörken; Peter Daniel
Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(5):1364-74.
1999: Udo Vanhoefer; Andreas Harstrick; Claus-Henning Köhne; Wolf Achterrath; Youcef M Rustum; Siegfried Seeber; Hansjochen Wilke
Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(3):907-13.
1998: Patrick Schöffski; M Freund; R Wunder; D Petersen; Claus-Henning Köhne; H Hecker; U Schubert; Arnold Ganser
Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study.
BMJ (Clinical research ed.) 1998;317(7155):379-84.
1998: Jörg Thomas Hartmann; Claus-Henning Köhne; H J Schmoll; Thomas Daikeler; Lothar Kanz; Carsten Bokemeyer
Is continuous 24-hour infusion of 5-fluorouracil plus high-dose folinic acid effective in patients with progressive or recurrent colorectal cancer? A phase II study.
Oncology 1998;55(4):320-5.
1998: Claus-Henning Köhne; Peter C Thuss-Patience; M Friedrich; Peter Daniel; Albrecht Kretzschmar; Thomas Benter; B Bauer; R Dietz; B Dörken
Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity.
British journal of cancer 1998;77(6):973-7.
1998: Claus-Henning Köhne; P Schöffski; Hansjochen Wilke; C Käufer; R Andreesen; U Ohl; U Klaasen; M Westerhausen; W Hiddemann; G Schott; A Harstick; J Bade; A Horster; U Schubert; H Hecker; B Dörken; H J Schmoll
Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(2):418-26.
1998: Matthias Lorenz; Elsbeth Staib-Sebler; Christiane Gog; Henrik Petrowsky; Claus-Henning Köhne; Albrecht Encke
A pilot study on intensive weekly 24-hour intra-arterial infusion with 5-fluorouracil and folinic acid for colorectal liver metastases.
Oncology 1998;55(1):53-8.
1997: Claus-Henning Köhne; Andreas Harstrick; W Hiddemann; Patrick Schöffski; Hansjochen Wilke; C Bokemeyer; B Dörken; H J Schmoll
Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate in patients with advanced colorectal cancer. Results of a phase II study.
European journal of cancer (Oxford, England : 1990) 1997;33(11):1896-9.
1997: Albrecht Kretzschmar; Claus-Henning Köhne; Bernd Dörken
[Docetaxel in treatment of other solid tumors].
Medizinische Klinik (Munich, Germany : 1983) 1997;92 Suppl 4():16-22.
1997: Andreas Harstrick; Claus-Henning Köhne; W Hiddemann; Peter Preusser; Dirk Strumberg; T Berns; S Seeber; Hansjochen Wilke; H J Schmoll
Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate (PALA) is inactive in advanced pancreatic carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(9):917-8.
1997: Claus-Henning Köhne; Thomas Benter
[After-care of colorectal carcinoma--value of tumor markers].
Der Internist 1997;38(4):363-5.
1997: Claus-Henning Köhne; Hansjochen Wilke; Wolfgang Hiddemann; Carsten Bokemeyer; H P Lohrmann; Heinrich Bodenstein; J Preiss; H Rauschecker; H Hill; C Kaufer; J Th Fischer; U Ohl; D Urbanitz; Leopold Balleisen; Hans-Joachim Schmoll
Phase II evaluation of 5-fluourouracil plus folinic acid and alpha 2b-interferon in metastatic colorectal cancer.
Oncology 1997;54(2):96-101.
1997: Claus-Henning Köhne; Peter Daniel; Bernd Dörken
The value of weekly high dose infusional 5-fluorouracil in the treatment of advanced colorectal cancer.
Tumori 1997;83(1 Suppl):S56-60.
1996: Carsten Bokemeyer; M A Kuczyk; Claus-Henning Köhne; A Haupt; H J Schmoll
[Risk of secondary neoplasia after treatment of malignant germ cell tumors of the testis].
Medizinische Klinik (Munich, Germany : 1983) 1996;91(11):703-10.
1996: Claus-Henning Köhne
[Progress in development of chemotherapy of colorectal carcinoma].
Medizinische Klinik (Munich, Germany : 1983) 1996;91 Suppl 3():33-7.
1996: Hansjochen Wilke; MW Korn; U Vanhöfer; U Fink; M Stahl; Peter Preusser; Claus-Henning Köhne; U Klassen; Andreas Harstrick; H J Schmoll; Siegfried Seeber
Weekly infusional 5-fluorouracil plus/minus other drugs for the treatment of advanced gastric cancer.
The Journal of infusional chemotherapy 1996;6(3):123-6.
1996: Claus-Henning Köhne; Hansjochen Wilke; Patrick Schöffski; H J Schmoll
The dead end of 5-fluorouracil double modulation and promise of continuous infusion schedules in the treatment of metastatic colorectal cancer.
The Journal of infusional chemotherapy 1996;6(4):206-10.
1995: Claus-Henning Köhne; Wolfgang Hiddemann; J Schüller; J Weiss; H P Lohrmann; U Schmitz-Hübner; H Bodenstein; C Schöber; Hansjochen Wilke; J Grem
Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(5):1201-8.
1995: Claus-Henning Köhne; Hansjochen Wilke; H Hecker; Patrick Schöffski; C Käufer; H Rauschecker; R Andreesen; U Ohl; H J Lange; U Klaassen
Interferon-alpha does not improve the antineoplastic efficacy of high-dose infusional 5-fluorouracil plus folinic acid in advanced colorectal cancer. First results of a randomized multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(5):461-6.